Premium
Successful treatment of anemia in idiopathic myelofibrosis with recombinant human erythropoietin
Author(s) -
Hasselbalch Hans Carl,
Clausen Nielsaage Tøffner,
Jensen Bjarne Anker
Publication year - 2002
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.10076
Subject(s) - myelofibrosis , erythropoietin , medicine , anemia , recombinant dna , blood transfusion , interferon , gastroenterology , immunology , bone marrow , biochemistry , chemistry , gene
Thirteen patients with idiopathic myelofibrosis (5 osteomyelosclerosis) were treated with recombinant human erythropoietin (rHuEpo) for transfusion‐dependent anemia. All but 7 patients were concomitantly treated with alpha interferon, and 5 patients also received a interferon before the start of erythropoietin (EPO) treatment. All but two patients became transfusion independent. The highly positive results of the present study of transfusion‐dependent patients with idiopathic myelofibrosis calls for further studies to delineate more precisely in larger series those patients who are likely to respond to rHuEpo. Am. J. Hematol. 70:92–99, 2002. © 2002 Wiley‐Liss, Inc.